Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial
Early-phase clinical data suggest this combination may also have beneficial effects on liver fat content, lipid profiles, and blood glucose control, though these observations require confirmation in larger, longer-duration studies
It is given as a once-weekly subcutaneous injection
SURPASS J-combo study comparing people with T2DM in a Japanese population with a high HbA1c on oral antihyperglycemic monotherapy on 5, 10, or 15 mg of once weekly tirzepatide for 52 weeks showed an improvement of glycemic and lipid control, weight loss and reduction in blood pressure [57]
Understand the difference between research-grade and pharmaceutical-grade peptides
Another meta-analysis, which looked at relevant data from multiple clinical studies, estimated that 40-70% of people on GLP-1 drugs will experience nausea at some point while taking the medication
